Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 5 (2008), Issue 9 (September)

1. Chemotherapeutic drugs and human tumor cells cytokine network.
   Int J Cancer, 123(9): 2031-40. [Abstract] [Full-text]
2. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
   Cancer Res, 68(17): 7083-9. [Abstract] [Full-text]
3. Trastuzumab Administration Associated with Change in HER2 Status.
   Clin Breast Cancer, 8(4): 366-9. [Abstract] [Full-text]
4. Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer.
   Clin Breast Cancer, 8(4): 324-33. [Abstract] [Full-text]
5. Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
   J Nucl Med, 49(9): 1498-505. [Abstract] [Full-text]
6. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
   J Nucl Med, 49(9): 1537-45. [Abstract] [Full-text]
7. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.
   Am J Health Syst Pharm, 65(18): 1703-10. [Abstract] [Full-text]
8. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
   Mol Cell Biol, 28(18): 5605-20. [Abstract] [Full-text]
9. Targeting Her-2/neu in breast cancer: as easy as this!
   Oncology, 74(3): 150-7. [Abstract] [Full-text]
10. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review.
    Cancer Treat Rev, 34(6): 539-57. [Abstract] [Full-text]
11. Trastuzumab-induced hepatotoxicity.
    Ann Pharmacother, 42(10): 1497-501. [Abstract] [Full-text]
12. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
    Cancer Chemother Pharmacol, 62(6): 1085-90. [Abstract] [Full-text]
13. Cutaneous vasculitis in breast cancer treated with chemotherapy.
    Clin Immunol, 129(1): 3-9. [Abstract] [Full-text]
14. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
    Cancer, 113(6): 1284-93. [Abstract] [Full-text]
15. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
    Cancer, 113(6): 1294-301. [Abstract] [Full-text]
16. HER-2-positive metastatic breast cancer: trastuzumab and beyond.
    Expert Opin Pharmacother, 9(15): 2583-601. [Abstract] [Full-text]
17. Ertumaxomab: a trifunctional antibody for breast cancer treatment.
    Expert Opin Investig Drugs, 17(10): 1553-8. [Abstract] [Full-text]
18. High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma.
    Appl Immunohistochem Mol Morphol, 16(5): 466-70. [Abstract] [Full-text]
19. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Pharmacotherapy, 28(10): 1255-66. [Abstract] [Full-text]
20. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.
    J Virol, 82(20): 10153-61. [Abstract] [Full-text]

© 2004-2010 Herceptin Research Today. All Rights Reserved.